USA

Resunab, a promising future treatment for lupus.

Resunab, a promising future treatment for lupus.

Patent holder Corbus Pharmaceuticals is putting the drug, branded Resunab, through its clinical paces.

Ajulemic acid (AJA, CT‐3, IP‐751, JBT‐101, anabasum) is a first‐in‐class, synthetic, orally active, cannabinoid‐derived drug that preferentially binds to the CB2 receptor and is non psychoactive.

In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability, and pharmacokinetic profile. It also demonstrated significant efficacy in preclinical models of inflammation and fibrosis.

Promising Screening Tools Assessed for Cognitive Dysfunction in SLE

Promising Screening Tools Assessed for Cognitive Dysfunction in SLE

The Montreal Cognitive Assessment (MoCA) questionnaire is an easy-to-administer, inexpensive, effective screening tool that can identify patients with systemic lupus erythematosus (SLE) who might be at risk for cognitive dysfunction (CD) and might benefit from additional neuropsychiatric assessment, according to data published in Lupus.

Recurrent lupus nephritis less frequent after kidney transplant

Recurrent lupus nephritis less frequent after kidney transplant

Lupus nephritis is recurring less frequently among patients with end-stage renal disease who undergo kidney transplant, possibly due to improved immunosuppression, according to data presented by Debendra N. Pattanaik, MBBS, MD, of the University of Tennessee Health Science Center.Lupus nephritis is recurring less frequently among patients with end-stage renal disease who undergo kidney transplant, possibly due to improved immunosuppression, according to data presented by Debendra N. Pattanaik, MBBS, MD, of the University of Tennessee Health Science Center.

Lupus patients benefited from bioelectronic medicine treatment

Lupus patients benefited from bioelectronic medicine treatment

A pilot clinical trial showed that bioelectronic medicine treatment was effective in reducing fatigue and pain in lupus patients. The researchers also saw a decrease in arthritis. A pilot study is a small-scale preliminary study that examines the feasibility of an approach that researchers intend to use in a larger scale study.

Organs are not just bystanders, may be active participants in fighting autoimmune disease

Organs are not just bystanders, may be active participants in fighting autoimmune disease

Organs affected by autoimmune disease could be fighting back by "exhausting" immune cells that cause damage using methods similar to those used by cancer cells to escape detection, according to a study by researchers at the University of Pittsburgh School of Medicine published today in the Journal of Clinical Investigation.

Lupus affects more women than men. Why? New study explores

Lupus affects more women than men. Why? New study explores

Lupus affects nine times more women than men. Experts know that lupus erythematosus, SLE, or lupus affects many more women than men, but none of them can explain why. Now that University of Houston biomedical engineer Chandra Mohan has the funding, he has set out to determine why.

Prof. Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, has $2 million to solve the mystery.